Takeda Pharmaceutica
4502
End-of-day quote Tokyo - 07/20
4728JPY
-0.13%
Prev.4734.0000
Open4759.0000
High4764.0000
Low4691.0000
Volume3 238 600
Financials
Sales 2019 1 762 B
EBIT 2019 -
R. net 2019 160 B
Debt 2019 680 B
Rend. 2019 3,81%
P/E ratio 2019 22,99
P/E ratio 2020 20,31
EV / Sales 2019 2,52x
EV / Sales 2020 2,36x
Capitalization 3 762 B
Company
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs.It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other.The Prescription Drugs segment includes the manufacture...
Sector :
Pharmaceuticals - NEC
Calendar :
2018-07-31 Earnings Release
Trading Rating :
Investor Rating :
Latest news
07/20TAKEDA PHARMACEUTICAL : Investigators from Takeda Pharmaceutical Company Have Reported New Data on Aspartic Acid Endopeptidases (Discovery of benzimidazole derivatives as...
AQ
07/20TAKEDA PHARMACEUTICAL : and Ovid partner to start TAK-935/OV935 clinical trials
AQ
07/20TAKEDA PHARMACEUTICAL : Phase 3 Trial of NINLAROŽ ixazomib as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in...
AQ
07/20TAKEDA PHARMACEUTICAL : New Findings from Takeda Pharmaceutical Company in the Area of Antibodies Described (Development of a chemically defined platform fed-batch culture...
AQ
07/20TAKEDA PHARMACEUTICAL : Patent Issued for Method for Producing Dopaminergic Neurons (USPTO 10017734)
AQ
07/19TAKEDA PHARMACEUTICAL : Investigational Subcutaneous Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Ulcerative Colitis
PU
07/19TAKEDA PHARMACEUTICAL : and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
AQ
07/19TAKEDA PHARMACEUTICAL : Submits an Application for a New Indication of Entyvio (vedolizumab) for the Treatment of Adult Patients With Moderately to Severely Active Crohn's Disease in Japan
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBearishBearish
Resistance4 7345 1175 349
Spread/Res.-0,13%-7,6%-12%
Spread/Supp.7,0%12%10%
Support4 4204 2034 290